Scorpius Holdings IncNYSE American:SCPX
- LAST PRICE0.1839
- TODAY'S CHANGE (%)0.0149 (8.8166%)
- Bid / Lots0.1818/ 6
- Ask / Lots0.1840/ 2
- Open / Previous Close0.1800 / 0.1690
- Day Range
- 52 Week Range
- Volume2,870,439
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SCPX |
|---|---|---|
| 09:32 ET | 9091 | 0.1839 |
Today
Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023, from 1 hour ago by Dow Jones
1 hour ago by Dow JonesPress Release: Scorpius Holdings Provides 2023 Year-End Business Update; Reports 570% Sequential Increase in Revenue for the Fourth Quarter of 2023, from 1 hour ago by Dow Jones
1 hour ago by Dow Jones
Apr 22, 2024
Scorpius Holdings Announces Receipt of Filing Delinquency Notification, from 5:00PM ET on Monday Apr 22, 2024 by Dow Jones
5:00PM ET on Monday Apr 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Scorpius Holdings Inc | 6.1M | -0.1x | --- |
Orexo AB | 52.8M | -4.1x | --- |
Parnell Pharmaceuticals Holdings Ltd | 20.0 | 0.0x | --- |
Targeted Medical Pharma Inc | 3.0K | 0.0x | --- |
Vapor Group Inc | 27.3K | 0.0x | --- |
Healthy Extracts Inc | 5.9M | -2.3x | --- |
Company Information
Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.
Contact Information
- Headquarters
- 627 DAVIS DRIVE, SUITE 400MORRISVILLE, NC, United States 27560
- Phone
- 919-240-7133
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Jeffrey Wolf
- Chief Financial Officer, Controller, Secretary
- William Ostrander
- Lead Independent Director
- John Prendergast
- Independent Director
- John Monahan
- Independent Director
- Edward Smith
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.1M |
|---|---|
Revenue (TTM) | $2.2M |
Shares Outstanding | 36.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.08 |
EPS | $-1.78 |
Book Value | $2.88 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 2.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,294.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
